## Angela Hoye

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7457164/publications.pdf Version: 2024-02-01



ANCELA HOVE

#	Article	IF	CITATIONS
1	Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the "Real Worldâ€: Circulation, 2004, 109, 190-195.	1.6	511
2	Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. Journal of the American College of Cardiology, 2005, 45, 947-953.	1.2	413
3	Percutaneous coronary intervention for chronic total occlusions: the Thoraxcenter experience 1992–2002. European Heart Journal, 2005, 26, 2630-2636.	1.0	316
4	Clinical, Angiographic, and Procedural Predictors of Angiographic Restenosis After Sirolimus-Eluting Stent Implantation in Complex Patients. Circulation, 2004, 109, 1366-1370.	1.6	305
5	Coronary Restenosis After Sirolimus-Eluting Stent Implantation. Circulation, 2003, 108, 257-260.	1.6	268
6	Long-Term Outcomes After Stenting of Bifurcation Lesions With the "Crush―Technique. Journal of the American College of Cardiology, 2006, 47, 1949-1958.	1.2	228
7	Long-Term Follow-Up of Elective Chronic Total Coronary Occlusion Angioplasty. Journal of the American College of Cardiology, 2014, 64, 235-243.	1.2	228
8	The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population. Journal of the American College of Cardiology, 2005, 45, 1135-1141.	1.2	204
9	Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions. Journal of the American College of Cardiology, 2004, 43, 1954-1958.	1.2	194
10	Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. Journal of the American College of Cardiology, 2004, 43, 704-708.	1.2	191
11	Stent fracture and restenosis in the drug-eluting stent era. Catheterization and Cardiovascular Interventions, 2004, 61, 111-116.	0.7	184
12	Incidence and clinical impact of coronary stent fracture after sirolimus-eluting stent implantation. Catheterization and Cardiovascular Interventions, 2007, 69, 380-386.	0.7	179
13	Value of preprocedure multislice computed tomographic coronary angiography to predict the outcome of percutaneous recanalization of chronic total occlusions. American Journal of Cardiology, 2005, 95, 240-243.	0.7	164
14	Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes. Journal of the American College of Cardiology, 2003, 41, 2093-2099.	1.2	150
15	Restenosis rates following bifurcation stenting with sirolimus-eluting stents for de novo narrowings. American Journal of Cardiology, 2004, 94, 115-118.	0.7	124
16	Global Chronic Total Occlusion CrossingÂAlgorithm. Journal of the American College of Cardiology, 2021, 78, 840-853.	1.2	111
17	Sirolimus-Eluting Stent Implantation in ST-Elevation Acute Myocardial Infarction. Circulation, 2003, 108, 1927-1929.	1.6	110
18	Association of Sex With Severity of Coronary Artery Disease, Ischemia, and Symptom Burden in Patients With Moderate or Severe Ischemia. JAMA Cardiology, 2020, 5, 773.	3.0	101

ANGELA HOYE

#	Article	IF	CITATIONS
19	Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents. American Journal of Cardiology, 2005, 95, 167-172.	0.7	92
20	Very long sirolimus-eluting stent implantation for de novo coronary lesions. American Journal of Cardiology, 2004, 93, 826-829.	0.7	91
21	Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial. Lancet, The, 2019, 393, 987-997.	6.3	72
22	Effectiveness of sirolimus-eluting stent for treatment of left main coronary artery disease. American Journal of Cardiology, 2003, 92, 327-329.	0.7	68
23	The occupational effects of interventional cardiology: results from the WIN for Safety survey. EuroIntervention, 2012, 8, 658-663.	1.4	57
24	Effectiveness of sirolimus-eluting stent implantation for recurrent in-stent restenosis after brachytherapy. American Journal of Cardiology, 2003, 92, 200-203.	0.7	51
25	Treatment of very small vessels with 2.25-mm diameter sirolimus-eluting stents (from the RESEARCH) Tj ETQq1	1 0,784314 0.7	1 rgBT /Over
26	Clinical outcomes for sirolimus-eluting stent implantation and vascular brachytherapy for the treatment of in-stent restenosis. Catheterization and Cardiovascular Interventions, 2004, 62, 283-288.	0.7	50
27	Incidence of thrombotic stent occlusion during the first three months after sirolimus-eluting stent implantation in 500 consecutive patients. American Journal of Cardiology, 2004, 93, 1271-1275.	0.7	46
28	Elective sirolimus-eluting stent implantation for left main coronary artery disease: Six-month angiographic follow-up and 1-year clinical outcome. Catheterization and Cardiovascular Interventions, 2004, 62, 292-296.	0.7	44
29	Local Drug Delivery Using Coated Stents: New Developments and Future Perspectives. Current Pharmaceutical Design, 2004, 10, 357-367.	0.9	37
30	Collateral Donor Artery Physiology and the Influence of a Chronic Total Occlusion on Fractional Flow Reserve. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	36
31	Multi-disciplinary palliative care is effective in people with symptomatic heart failure: A systematic review and narrative synthesis. Palliative Medicine, 2019, 33, 1003-1016.	1.3	36
32	Effectiveness of the sirolimus-eluting stent in the treatment of saphenous vein graft disease. Journal of Invasive Cardiology, 2004, 16, 230-3.	0.4	36
33	Medical therapy, percutaneous coronary intervention and prognosis in patients with chronic total occlusions. Heart, 2015, 101, 1907-1914.	1.2	34
34	Percutaneous therapy of bifurcation lesions with drugâ€eluting stent implantation: the Culotte technique revisited. International Journal of Cardiovascular Interventions, 2005, 7, 36-40.	0.5	32
35	Effectiveness of sirolimus-eluting stent implantation for the treatment of coronary artery disease in octogenarians. American Journal of Cardiology, 2004, 94, 909-913.	0.7	24
36	Dedicated Bifurcation Stent for the Treatment of Bifurcation Lesions InvolvingÂLarge Side Branches. JACC: Cardiovascular Interventions, 2016, 9, 1338-1346.	1.1	22

ANGELA HOYE

#	Article	IF	CITATIONS
37	Improved recanalization of chronic total coronary occlusions using an optical coherence reflectometry-guided guidewire. Catheterization and Cardiovascular Interventions, 2004, 63, 158-163.	0.7	21
38	Gender-based issues in interventional cardiology: a consensus statement from the Women in Innovations (WIN) initiative. EuroIntervention, 2010, 5, 773-779.	1.4	21
39	The Proximal Optimisation Technique for Intervention of Coronary Bifurcations. Interventional Cardiology Review, 2017, 12, 110.	0.7	19
40	Clinical and angiographic outcomes after overdilatation of undersized sirolimus-eluting stents with largely oversized balloons: An observational study. Catheterization and Cardiovascular Interventions, 2004, 61, 455-460.	0.7	17
41	Genderâ€based issues in interventional cardiology: A consensus statement from the Women in Innovations (WIN) Initiative. Catheterization and Cardiovascular Interventions, 2010, 75, 145-152.	0.7	17
42	Drug-eluting stent implantation for chronic total occlusions: comparison between the Sirolimus- and Paclitaxel-eluting stent. EuroIntervention, 2005, 1, 193-7.	1.4	17
43	Elective sirolimus-eluting stent implantation for multivessel disease involving significant LAD stenosis: One-year clinical outcomes of 99 consecutive patients?the Rotterdam experience. Catheterization and Cardiovascular Interventions, 2004, 63, 57-60.	0.7	16
44	Bifurcation stenting with drug eluting stents: Illustration of the crush technique. Catheterization and Cardiovascular Interventions, 2006, 67, 839-845.	0.7	16
45	Focus on the research utility of intravascular ultrasound - comparison with other invasive modalities. Cardiovascular Ultrasound, 2011, 9, 2.	0.5	15
46	Management of chronic total occlusion by percutaneous coronary intervention. Heart, 2012, 98, 822-828.	1.2	15
47	Clinical Indications for Intravascular Ultrasound Imaging. Echocardiography, 2010, 27, 1282-1290.	0.3	14
48	Prospective cohort study of elderly patients with coronary artery disease: impact of frailty on quality of life and outcome. Open Heart, 2020, 7, e001314.	0.9	14
49	Systematic review and meta-analysis of optimal P2Y <sub>12</sub> blockade in dual antiplatelet therapy for patients with diabetes with acute coronary syndrome. Open Heart, 2016, 3, e000296.	0.9	13
50	Effectiveness of sirolimus-Eluting stent implantation for coronary narrowings <50% in diameter. American Journal of Cardiology, 2004, 94, 112-114.	0.7	12
51	Outcomes After Percutaneous Coronary Intervention in Women: Are There Differences When Compared with Men?. Interventional Cardiology Review, 2019, 14, 70-75.	0.7	12
52	Treatment of de novo bifurcation lesions: comparison of Sirolimus- and Paclitaxel-eluting stents. EuroIntervention, 2005, 1, 24-30.	1.4	11
53	GuideLiner-Facilitated Rotational Atherectomy in Calcified Right CoronaryÂArtery. JACC: Cardiovascular Interventions, 2016, 9, e47-e48.	1.1	9
54	The haemodynamic effects of collateral donation to a chronic total occlusion: Implications for patient management. International Journal of Cardiology, 2015, 198, 159-166.	0.8	8

ANGELA HOYE

#	Article	IF	CITATIONS
55	Microvascular dysfunction in the immediate aftermath of chronic total coronary occlusion recanalization. Catheterization and Cardiovascular Interventions, 2016, 87, 1071-1079.	0.7	8
56	Spontaneous coronary artery dissection: time for a concerted effort to better understand this rare condition. Journal of Invasive Cardiology, 2010, 22, 229-30.	0.4	8
57	Sirolimusâ€Eluting Stent Implantation for Chronic Total Occlusion of the Left Main Coronary Artery. Journal of Interventional Cardiology, 2005, 18, 65-69.	0.5	7
58	Cuestiones relativas al sexo en cardiologÃa intervencionista: declaración de consenso de la iniciativa Women in Innovations (WIN). Revista Espanola De Cardiologia, 2010, 63, 200-208.	0.6	7
59	Effectiveness of the sirolimus-eluting stent in the treatment of patients with a prior history of coronary artery bypass graft surgery. Coronary Artery Disease, 2004, 15, 171-175.	0.3	6
60	New Approaches to Ostial and Bifurcation Lesions. Journal of Interventional Cardiology, 2004, 17, 397-403.	0.5	5
61	Response to Letter Regarding Article, "Collateral Donor Artery Physiology and the Influence of a Chronic Total Occlusion on Fractional Flow Reserve― Circulation: Cardiovascular Interventions, 2015, 8, e002796.	1.4	5
62	Intravenous versus intracoronary bolus of glycoprotein IIb/IIIa inhibitor administration during primary percutaneous coronary intervention on long-term left ventricular systolic and diastolic function. Cardiology Journal, 2013, 20, 310-317.	0.5	5
63	Exercise Training as a Mediator for Enhancing Coronary Collateral Circulation: A Review of the Evidence. Current Cardiology Reviews, 2020, 16, 212-220.	0.6	5
64	Paclitaxel eluting stents for the treatment of angiographically nonâ€significant atherosclerotic lesions. International Journal of Cardiovascular Interventions, 2005, 7, 68-71.	0.5	4
65	Influence of case definition on incidence and outcome of acute coronary syndromes. Open Heart, 2016, 3, e000487.	0.9	4
66	Gender-Based Issues in Interventional Cardiology: a Consensus Statement from the Women in Innovations (WIN) Initiative. Revista Espanola De Cardiologia (English Ed ), 2010, 63, 200-208.	0.4	3
67	latrogenic hyperkalaemia. Lancet, The, 2003, 361, 2124.	6.3	2
68	Reply. Journal of the American College of Cardiology, 2014, 64, 2709-2710.	1.2	2
69	Is there Sex-related Outcome Difference According to oral P2Y12 Inhibitors in Patients with Acute Coronary Syndromes? A Systematic Review and Meta-Analysis of 107,126 Patients. Current Vascular Pharmacology, 2019, 17, 191-203.	0.8	2
70	Successful use of a new guidewire with radiofrequency ablation capability for the treatment of chronic total occlusion at the ostium of the left anterior descending artery. Journal of Invasive Cardiology, 2005, 17, 277-9.	0.4	2
71	The CAPTIM study. Lancet, The, 2003, 361, 700.	6.3	1
72	AS-034 Impact of Therapy (medical versus revascularization) on the Long-Term Survival of Patients with Coronary Disease Including a Chronic Total Occlusion. American Journal of Cardiology, 2011, 107, 14A-15A.	0.7	1

Angela Hoye

#	Article	IF	CITATIONS
73	Percutaneous Treatment of Chronic Total Occlusions. , 2013, , 593-609.		1
74	Cardiogoniometry Compared to Fractional Flow Reserve at Identifying Physiologically Significant Coronary Stenosis: The CARDIOFLOW Study. Cardiovascular Engineering and Technology, 2018, 9, 439-446.	0.7	1
75	Proprotein Convertase Subtilisin/kexin type 9 Inhibition in Cardiovascular Prevention. Current Pharmaceutical Design, 2018, 24, 442-450.	0.9	1
76	AS-184 Impact of Myocardial Viability on the Long Term Survival of Patients with A Coronary Chronic Total Occlusion. American Journal of Cardiology, 2011, 107, 61A.	0.7	0
77	TCT-326 The Occupational Effects of Interventional Cardiology Results from the WIN for Safety Survey. Journal of the American College of Cardiology, 2012, 60, B92.	1.2	0
78	Outcome of Transcatheter Mitral Valve Clip for the Management of Mitral Regurgitation in High Risk Group Patients Unsuitable for Surgical Intervention. American Journal of Cardiology, 2013, 111, 58B.	0.7	0
79	Preintervention evaluation of chronic total occlusions. , 2009, , 16-23.		Ο
80	Examining access routes and bleeding risk in women undergoing percutaneous coronary intervention. Interventional Cardiology, 2013, 5, 419-425.	0.0	0
81	Editorial. Interventional Cardiology Review, 2016, 11, 8.	0.7	0
82	Implications of Intracoronary Ultrasound Imaging for Clinical Practice. Advances in Bioinformatics and Biomedical Engineering Book Series, 0, , 94-108.	0.2	0
83	Current Status of Intravascular Imaging with IVUS and OCT. Advances in Bioinformatics and Biomedical Engineering Book Series, 0, , 293-308.	0.2	0
84	The how and why of Chronic Total Occlusions. Part Two: Why we treat CTOs the way we do. EuroIntervention, 2006, 2, 382-8.	1.4	0